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sions using conventional endoscopic methods. The CDAI is 
widely used in assessing disease activity; however, clinical 
symptoms scored by CDAI are not reliable measures of mu-
cosal inflammation.3 Computerized tomography enterogra-
phy (CTE) imaging is useful for assessing disease activity in 
CD but exposes patients to a large dose of radiation during 
each evaluation, therefore preventing repeated examina-
tions.4
In recent years, magnetic resonance enterography (MRE) 
has emerged as an important tool in the diagnosis and 
follow-up of CD.5 MRE can provide information on the deep 
small intestine and extraluminal manifestations of CD.6 MRE 
is preferred because it does not expose patients to ionizing 
radiation, has a high tissue contrast, and uses safe gadolini-
um-based contrast media.7 A correlation between MRE im-
aging and the disease activity of CD has been established.8 In 
a meta-analysis study, the sensitivity and specificity of MRI 
for the detection of CD were found to be 93.0% and 92.8%, 
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Crohn’s disease (CD) is a chronic transmural IBD that can 
occur throughout the gastrointestinal tract. It is character-
ized by repeated episodes of exacerbation and regression. 
Approximately 70% of patients with CD have small-bowel 
involvement, and 30% of them have disease limited to the 
small bowel.1 Mucosal healing has become the treatment 
target in the management of CD.2 However, it is difficult to 
recognize mucosal lesions in patients with small-bowel le-
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Background/Aims: Magnetic resonance enterography (MRE) has emerged as an important tool in the diagnosis and follow-
up of Crohn’s disease (CD). The aim of this study was to evaluate whether MRE findings could predict the prognosis of CD. 
Methods: In this retrospective study, a total of 173 patients with clinical remission of CD (n=61) or active CD (n=112) were 
identified. The outcomes of clinical relapse, admission, surgery, and need for other medications according to the MRE findings 
were evaluated. Results: The presence of active inflammation on MRE was observed in 93 (83%) patients with clinically active 
CD and in 44 (72.1%) patients with clinical remission of CD, without a statistically significant difference (P=0.091). In multivari-
ate analysis, active inflammation on MRE increased the risk for clinical relapse (hazard ratio [HR], 6.985; 95% confidence in-
terval [CI], 1.024−47.649) in patients with clinical remission of CD. In patients with clinically active CD, active inflammation on 
MRE increased the risk for CD-related hospitalization (HR, 2.970; 95% CI, 1.006−8.772). Conclusions: The presence of active 
inflammation on MRE was significantly associated with poor prognosis both in patients with clinical remission of CD and in 
those with active CD. (Intest Res 2018;16:445-457)
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respectively.9 In other study, MRE detected ulcerative lesions 
in the small intestine with 82.4% sensitivity and 87.6% speci-
ficity.10 In another study assessing ileocolonic CD, MRE im-
aging was superior to CTE in detecting intestinal strictures 
and ileal wall enhancement.11
In a recent study, Deepak et al.12 revealed that radiological 
response detected with CTE or MRE was associated with a 
reduction in the long-term risk of hospitalization, surgery, 
or corticosteroid use among patients with small-bowel CD. 
However, few studies have evaluated the prognosis of pa-
tients with CD in terms of the first MRE findings both at the 
time of clinical remission and during the clinically active 
state. Therefore, the purpose of our study was to evaluate the 
usefulness of MRE imaging in assessing the prognosis of CD. 
We hypothesized that active inflammatory findings on MRE 
would be associated with poor prognosis such as relapse, 
admission, surgery, need for corticosteroids, need for adding 
other medications, or need for increasing the dose of current 
medications even in patients with clinical remission of CD.
METHODS
1. Patients
In this retrospective study, we reviewed the medical re-
cords of patients with CD who underwent MRE imaging at 
Severance Hospital, Yonsei University College of Medicine, 
Seoul, Korea, between December 2012 and March 2016. The 
purposes of MRE imaging evaluation were divided into 2 cat-
egories: evaluation of current CD activity at the time of clini-
cal remission and that during the clinically active state. MRE 
was performed in order to follow-up after the treatment. The 
indications for MRE were when the symptoms persisted 
despite treatment, complications were suspected, inflamma-
tory markers were elevated even with clinical remission, and 
determination of the appropriateness of current treatment. 
The CDAI according to the criteria of Best et al.13 was used to 
assess the disease activity of patients with CD. A CDAI score 
<150 was considered to indicate clinical remission. Clini-
cal relapse was defined as the occurrence or worsening of 
symptoms, accompanied by an increase in the CDAI score 
to >150.14
Descriptions of patient age at CD diagnosis, disease loca-
tion, and phenotype were based on the Montreal classifica-
tion.15 Previous surgery was defined as a prior CD-related 
surgery that includes major surgeries such as ileocecectomy 
and small-bowel resection. The exclusion criteria were pa-
tient age <18 years, inaccurate diagnosis of CD, <3 months of 
follow-up, and any contraindications to MRE imaging such 
as the presence of a pacemaker in patients.
Admission was defined as hospitalization for >1 day 
through the emergency room or outpatient clinic. Surgery 
was defined as any CD-related surgeries such as small-bow-
el resection and ileocecectomy. The need for corticosteroids 
was defined as the addition of any amount of corticosteroids 
in patients who were not steroid users during the follow-up 
period after MRE examination. The need for adding other 
medications or increasing the dose of current medications 
was defined as the addition of another type of CD medica-
tion or increasing the dose of medications used after MRE 
examination including corticosteroids, respectively. The 
study was approved by the Institutional Review Board of 
Severance Hospital (IRB No. 4-2016-0857) and performed 
in accordance with the principles of the Declaration of Hel-
sinki. The informed consent was waived.
2. MRE Technique
We used very low concentration of barium suspension (easy 
Mark 0.1; Taejoon Pharmaceutical, Seoul, Korea) for luminal 
distension of small bowel. Patients were given 1,350 mL of 
this solution orally 60 minutes before MRI. A 3-T imaging unit 
Fig. 1. Recruitment algorithm. A total of 
243 consecutive patients with magnetic 
resonance enterography (MRE) were en-
rolled. After 70 patients were excluded 
according to our exclusion criteria, a total 
of 173 patients were selected for statistical 
analysis. 
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(Achieva 3T; Philips, Best, the Netherlands or Discovery 750; 
GE Healthcare, Milwaukee, WI, USA) was used. Briefly, the fol-
lowing sequences were performed: coronal T2-weighted half-
Fourier sequences with and without fat suppression; coronal 
and axial T2-like steady-state gradient-echo sequences with 
fat suppression; coronal free breathing diffusion-weighted 
imaging (with b factors of 0, 500, and 800 s/mm2) and appar-
ent diffusion coefficient mapping; and coronal T1-weighted 
spoiled gradient-echo sequences with fat suppression, includ-
ing unenhanced imaging and dynamic phases sequences 
Table 1. Baseline Characteristics of Patients with CD on the Day of MRE Examination
Characteristics Total patients (n=173) Clinical remission state (n=61) Clinically active state (n=112) P-value
Male sex 127 (73.4) 45 (73.8) 82 (73.2) 0.937
Age (yr) 29 (24−37) 27 (23−38) 30 (24−36) 0.787
Age at diagnosis of CD (yr) 21 (18−27) 20 (17−27) 21 (18−27) 0.702
Age at diagnosis of CD 0.104
   A1 31 (17.9) 14 (23.0) 17 (15.2)
   A2 134 (77.5) 42 (68.9) 92 (82.1)
   A3 8 (4.6) 5 (8.2) 3 (2.7)
BMI (kg/m2) 20 (18−22) 21 (19−24) 19 (18−22)  0.012
Disease duration (yr) 7 (4−11) 8 (4−12) 7 (3−11) 0.694
Smoking 0.109
   Current  22 (12.7) 7 (11.5) 15 (13.4)
   Former  31 (17.9) 16 (26.2) 15 (13.4)
   Never 120 (69.4) 38 (62.3) 82 (73.2)
Baseline CDAI score 183 (117−249) 95 (61−122) 228 (187−277) <0.001
Baseline CRP level (mg/L) 6.2 (1.1−20.6) 2.8 (0.7−8.8) 11.1 (2.3−25.8) <0.001
Baseline ESR level (mm/hr) 27 (13−49) 23 (12−38) 30 (13−57) 0.003
Baseline albumin level (g/dL) 4.1 (3.7−4.3) 4.2 (4.0−4.5) 3.9 (3.6−4.2) <0.001
Disease localization 0.045
   L1 56 (32.4) 23 (37.7) 33 (29.5)
   L2 18 (10.4) 10 (16.4) 8 (7.1)
   L3 99 (57.2) 28 (45.9) 71 (63.4)
   L4 0 0 0 
Disease behavior 0.784
   B1 65 (37.6) 25 (40.9) 40 (35.7)
   B2 44 (25.4) 15 (24.6) 29 (25.9)
   B3 64 (36.9) 21 (34.4) 43 (38.4)
Perianal lesion 86 (49.7) 30 (49.2) 56 (50.0) 0.918
Previous surgery 48 (27.7) 17 (27.9) 31 (27.7) 0.979
Family history of IBD 5 (2.9) 1 (1.6) 4 (3.6) 0.658
Median follow-up period (mo) 15.9 (11.8−22.3) 14.4 (9.9−20.1) 17.7 (12.3−22.9) 0.002
MRE findings 0.091
   Active inflammation 137 (79.2) 44 (72.1) 93 (83.0)
   Inactive  36 (20.8) 17 (27.9) 19 (17.0)
Values are presented as median (interquartile range) or number (%).
MRE, magnetic resonance enterography.
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performed after intravenous administration of gadolinium-
based contrast material (Gadovist; Schering, Berlin, Germany) 
(0.2 mmol/kg at a rate of 2 mL/s) followed by a saline bolus 
injection and an axial delayed contrast-enhanced T1-weighted 
spoiled gradient-echo sequence with fat suppression. To 
avoid bowel peristalsis, 10 mg scopolamine-N-butyl bromide 
(Buscopan; Boehringer-Ingelheim, Ingelheim, Germany) was 
administered intravenously, immediately before imaging. An 
additional same dose of scopolamine was injected immedi-
ately before the contrast-enhanced T1-weighted imaging.
3. Image Analysis
The MRE images were reviewed retrospectively by 2 expe-
rienced radiologists (J.S.L. and N.S.) who were blinded to the 
clinical and laboratory findings of the patients. Active inflam-
mation on MRE was defined as the presence of more than 
one of the following findings: mural thickening >3 mm, mural 
hyperenhancement, mural edema (increased signal intensi-
ty on T2-weighted images), comb sign (sign of engorged vasa 
recta), penetration (sinus tract, fistula, abscess), or restricted 
Table 2. Baseline Characteristics of Patients with Clinical Remission of CD: Comparison between Patients with and Those without Active Inflammation
Characteristics Total patients (n=61) Active inflammation group (n=44) Inactive group (n=17) P-value
Male sex 45 (73.8) 34 (77.3) 11 (64.7) 0.344
Age (yr) 27 (23−38) 27 (23−37)  31 (20−46) 0.760
Age at diagnosis of CD (yr) 20 (17−27) 20 (17−25)  21 (16−33) 0.608
Age at diagnosis of CD 0.344
   A1 14 (23.0) 8 (18.2) 6 (35.3)
   A2 42 (68.9) 32 (72.7) 10 (58.8)
   A3 5 (8.2) 4 (9.1) 1 (5.9)
BMI (kg/m2) 21 (19−24) 21 (19−23)   21 (20−24) 0.729
Disease duration (yr) 8 (4−12) 7.5 (4−11) 9 (4−13) 0.353
Smoking 0.834
   Current 7 (11.5)  6 (13.6) 1 (5.9)
   Former 16 (26.2) 11 (25.0)  5 (29.4)
   Never 38 (62.3) 27 (61.4) 11 (64.7)
Baseline CDAI score  95 (61−122) 96 (61−120)    82 (62−128) 0.888
Baseline CRP level (mg/L) 2.8 (0.7−8.8) 4.3 (1.0−10.5)  0.8 (0.5−3.2) 0.003
Baseline ESR level (mm/hr) 23 (12−38) 25 (16−41)  11 (4−31) 0.052
Baseline albumin level (g/dL) 4.2 (4.0−4.5) 4.2 (3.8−4.4)  4.4 (4.2−4.6) 0.008
Disease localization 0.001
   L1 23 (37.7) 19 (43.2) 4 (23.5)
   L2 10 (16.4) 2 (4.5) 8 (47.1)
   L3 28 (45.9) 23 (52.3) 5 (29.4)
   L4 0 0 0
Disease behavior 0.584
   B1 25 (40.9) 16 (36.4) 9 (52.9)
   B2 15 (24.6) 12 (27.3) 3 (17.6)
   B3 21 (34.4) 16 (36.4) 5 (29.4)
Perianal lesion 30 (49.2) 24 (54.5) 6 (35.3) 0.178
Previous surgery 17 (27.9) 11 (25.0) 6 (35.3) 0.527
Family history of IBD 1 (1.6) 1 (2.3) 0 1.000
Median follow-up period (mo) 14.4 (9.9−20.1) 14.0 (10.3−19.0) 14.5 (8.6−21.7) 0.737
Values are presented as median (interquartile range) or number (%).
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diffusion on diffusion-weighted images.16-20 Mucosal healing 
was defined as the absence of any findings of active inflam-
mation.
4. End Points
The end points were the rates of clinical relapse, admis-
sion, surgery, need for corticosteroids, need for adding other 
medications, or need for increasing the dose of current med-
ications according to the purpose of the MRE examination.
5. Statistical Analysis
Statistical analyses were conducted by using SPSS version 
18.0 (SPSS Inc., Chicago, IL, USA). Continuous variables 
were compared by using the two-sample t-test or the Mann-
Whitney U-test. The chi-square test or Fisher exact test was 
used to analyze categorical data. The cumulative probabili-
ties of clinical relapse, admission, CD-related surgery, need 
for corticosteroids, need for adding other medications, or 
need for increasing the dose of current medications were es-
Table 3. Baseline Characteristics of Patients with Clinically Active CD: Comparison between Patients with and Those without Active Inflammation
Characteristics Total patients (n=112) Active inflammation group (n=93) Inactive group (n=19) P-value
Male sex 82 (73.2) 70 (75.3) 12 (63.2) 0.277
Age (yr) 30 (24−36) 30 (24−37) 28 (25−34) 0.944
Age at diagnosis of CD (yr) 21 (18−27) 21 (18−27) 21 (18−25) 0.946
Age at diagnosis of CD 0.413
   A1 17 (15.2) 16 (17.2) 1 (5.3)
   A2 92 (82.1) 74 (79.6) 18 (94.7)
   A3 3 (2.7) 3 (3.2) 0 
BMI (kg/m2) 19.3 (17.7−21.6) 19.4 (17.6−21.6) 19.1 (18.3−23.1) 0.673
Disease duration (yr) 7 (3−11) 7 (3−11) 6 (4−13) 0.985
Smoking 0.149
   Current 15 (13.4) 12 (12.9) 3 (15.8)
   Former 15 (13.4) 15 (16.1) 0 
   Never 82 (73.2) 66 (71.0) 16 (84.2)
Baseline CDAI score 228 (187−277) 221 (185−280) 248 (210−277) 0.550
Baseline CRP level (mg/L) 11.1 (2.3−25.8) 14 (4.2−28.2) 2 (0.6−7.4) <0.001
Baseline ESR level (mm/hr) 30 (13−57) 32 (18−60) 13 (8−30) <0.001
Baseline albumin level (g/dL) 3.9 (3.6−4.2) 3.9 (3.5−4.2) 4.3 (4.1−4.4) <0.001
Disease localization 0.163
   L1 33 (29.5) 24 (25.8) 9 (47.4)
   L2 8 (7.1) 7 (7.5) 1 (5.3)
   L3 71 (63.4) 62 (66.7) 9 (47.4)
   L4 0 0 0 
Disease behavior 0.733
   B1 40 (35.7) 33 (35.5) 7 (36.8)
   B2 29 (25.9) 23 (24.7) 6 (31.6)
   B3 43 (38.4) 37 (39.8) 6 (31.6)
Perianal lesion 56 (50.0) 48 (51.6)) 8 (42.1) 0.450
Previous surgery 31 (27.7) 23 (24.7) 8 (42.1) 0.123
Family history of IBD 4 (3.6) 4 (4.3) 0 1.000
Median follow-up period (mo) 17.7 (12.3−22.9) 18.1 (12.4−22.9) 17.2 (12.0−23.5) 0.824
Values are presented as median (interquartile range) or number (%).
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timated by using the Kaplan-Meier method and the log-rank 
test. A Cox proportional hazards model was used for assess-
ing the risk of clinical relapse, admission, CD-related surgery, 
need for corticosteroids, need for adding other medications, 
or need for increasing the dose of current medications. A P-
value of <0.05 was considered statistically significant.
RESULTS
A total of 173 consecutive patients with CD who met the 
Table 4. Univariate and Multivariate HR for Relapse and Need for Adding Other Medications or Increasing the Dose of Current Medications in Patients 
with Clinical Remission of CD
Outcomes Variable
Univariate Multivariate
HR (95% CI) P-value HR (95% CI) P-value
Relapse Male sex 0.531 (0.222–1.267) 0.154 0.337 (0.105–1.084) 0.068
Age 1.019 (0.994–1.045) 0.140 - - 
Age at diagnosis of CD 1.030 (1.003–1.058) 0.031 - -
Age at diagnosis of CD -
   A1 (Reference) (Reference)
   A2 1.738 (0.501–6.032) 0.384 0.821 (0.181–3.718) 0.799
   A3 4.010 (0.894–17.994) 0.070 0.252 (0.019–3.352) 0.297
BMI 1.012 (0.891–1.150) 0.851 - -
Disease duration 0.975 (0.903–1.052) 0.508 0.998 (0.901–1.105) 0.967
Smoking - -
   Current 1.895 (0.616–5.828) 0.265
   Former 0.950 (0.338–2.668) 0.922
   Never (Reference)
Baseline CDAI score 1.007 (0.996–1.019) 0.223 1.010 (0.994–1.026) 0.241
Baseline CRP level 1.023 (0.998–1.049) 0.077 - -
Baseline CRP >20 mg/dL 1.657 (0.556–4.944) 0.365 0.647 (0.111–3.780) 0.629
Baseline ESR level 1.012 (0.992–1.032) 0.237 - -
Baseline albumin level 0.302 (0.125–0.730) 0.008 - -
Baseline albumin ≤3.5 g/dL 3.900 (1.427–10.659) 0.008 7.968 (1.008–62.969) 0.049
Disease localization
   L1 (Reference) (Reference)
   L2 0.112 (0.014–0.911) 0.041 0.017 (0.000–0.686) 0.031
   L3 0.552 (0.230–1.325) 0.183 0.815 (0.249–2.662) 0.735
Disease behavior
   B1 (Reference) (Reference)
   B2 2.119 (0.711–6.315) 0.178 0.912 (0.122–6.806) 0.928
   B3 2.026 (0.720–5.705) 0.181 1.446 (0.370–5.649) 0.596
Perianal lesion 0.677 (0.289–1.589) 0.370 0.378 (0.090–1.593) 0.185
Previous surgery 1.155 (0.471–2.835) 0.753 1.618 (0.396–6.610) 0.503
Family history of IBD 1.751 (0.230–13.352) 0.589 - -
MRE findings
   Active inflammation 4.555 (1.063–19.511) 0.041 8.603 (1.026–72.138) 0.047
   Inactive  (Reference)  (Reference)
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inclusion criteria were included in this study (Fig. 1). The 
baseline characteristics of the patients on the day of MRE ex-
amination are summarized in Table 1. There were 127 male 
(73.4%) and 46 female (26.6%) patients whose median age 
at diagnosis was 21 years (interquartile range [IQR], 18−27 
years). The median BMI was 20 kg/m2 (IQR, 18−22 kg/m2), 
and the median duration of disease was 7 years (IQR, 4−11 
years).
The median CDAI on the day of MRE examination was 




HR (95% CI) P-value HR (95% CI) P-value
Adding other medications 
or increasing the dose of 
current medications
Male sex 1.085 (0.433–2.719) 0.862 0.699 (0.238–2.049) 0.514
Age 0.981 (0.947–1.016) 0.288 - -
Age at diagnosis of CD 0.978 (0.935–1.024) 0.346 - -
Age at diagnosis of CD
   A1 (Reference) (Reference)
   A2 0.761 (0.315–1.835) 0.543 0.407 (0.134–1.231) 0.111
   A3 0.340 (0.042–2.774) 0.314 0.147 (0.008–2.595) 0.191
BMI 1.024 (0.898–1.168) 0.719 - -
Disease duration 0.977 (0.911–1.048) 0.518 0.971 (0.889–1.061) 0.518
Smoking - -
   Current 1.400 (0.407–4.813) 0.593
   Former 0.924 (0.361–2.365) 0.870
   Never (Reference)
Baseline CDAI score 1.000 (0.990–1.011) 0.974 1.006 (0.992–1.020) 0.406
Baseline CRP level 1.003 (0.975–1.032) 0.841 - -
Baseline CRP >20 mg/dL 1.026 (0.307–3.431) 0.967 0.747 (0.152–3.672) 0.720
Baseline ESR level 0.998 (0.979–1.019) 0.882 - -
Baseline albumin level 0.527 (0.231–1.200) 0.127 - -
Baseline albumin ≤3.5 g/dL 0.903 (0.213–3.834) 0.890 0.915 (0.140–5.969) 0.926
Disease localization
   L1 (Reference) (Reference)
   L2 0.514 (0.141–1.872) 0.313 0.973 (0.184–5.149) 0.974
   L3 0.897 (0.387–2.081) 0.800 0.678 (0.241–1.902) 0.460
Disease behavior
   B1 (Reference) (Reference)
   B2 1.001 (0.356–2.814) 0.998 1.572 (0.333–7.421) 0.568
   B3 1.283 (0.521–3.157) 0.588 1.757 (0.540–5.717) 0.349
Perianal lesion 1.685 (0.757–3.753) 0.202 1.271 (0.451–3.582) 0.650
Previous surgery 0.830 (0.331–2.079) 0.691 0.659 (0.180–2.417) 0.530
MRE findings
   Active inflammation 3.515 (1.051–11.755) 0.041 5.113 (1.187–22.029) 0.029
   Inactive  (Reference)  (Reference)
HR, hazard ratio; MRE, magnetic resonance enterography.
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and 228 (IQR, 187−277) in patients with clinically active CD 
(P <0.001). The median CRP level and ESR were higher in 
patients with clinically active CD than in those with clinical 
remission of CD (P<0.001 and P=0.003, respectively), and the 
median albumin level was lower in patients with clinically 
active CD (P<0.001). Almost half of the patients (49.7%) had 
perianal lesions, and 71 patients (41%) had a previous CD-
related surgery. The median follow-up period after MRE was 
14.4 months (IQR, 9.9−20.1 months) in patients with clinical 
remission of CD and 17.7 months (IQR, 12.3−22.9 months) 
in those with clinically active CD (P<0.001).
The presence of active inflammation on MRE was ob-
served in 93 (83.0%) patients with clinically active CD and 
in 44 (72.1%) patients with clinically remission of CD, with 
no statistically significant difference (P =0.091). More than 
72% of patients with clinical remission of CD still had active 
inflammation on MRE examination.
A total of 61 patients were in the clinical remission state, 
and their baseline characteristics according to the MRE re-
sults are detailed in Table 2. Forty-four patients (72.1%) had 
active inflammation on MRE, and their median CRP was 
higher than that of patients with no active inflammation on 
MRE (P=0.003). The median albumin level was significantly 
lower in the group with active inflammation than in the 
group without (P=0.008). 
A total of 112 patients were in the clinically active state, 
and their baseline characteristics are summarized in Table 
3. The median CRP level and ESR were higher in the group 
with active inflammation (P<0.001 and P<0.001, respective-
ly), and the median albumin level was higher in the group 
without active inflammation (P<0.001).
1. Medication Use
The medications used at the time of MRE examination 
among patients with clinical remission of CD were 5-ami-
nosalicylic acid (5-ASA) in 56 patients (91.8%), azathioprine 
in 34 patients (55.7%), tumor necrosis factor α (TNF-α) 
inhibitors in 10 patients (16.4%), corticosteroids in 1 pa-
tient (1.6%), methotrexate in 1 patient (1.6%), and none in 1 
patient (1.6%). Among 61 patients in the clinical remission 
state, the need for adding other medications or increasing 
the dose of current medications was observed in 24 patients 
(39.3%), and of these, addition of corticosteroids was ob-
served in 5 patients (8.2%).
The medications used at the clinically active state of CD 
were 5-ASA in 95 patients (84.8%), azathioprine in 64 pa-
tients (57.1%), TNF-α inhibitors in 27 patients (24.1%), cor-
ticosteroids in 7 patients (6.3%), methotrexate in 2 patients 
(1.8%), and none in 1 patient (0.9%). Among 112 patients 
with clinically active CD, the need for adding other medica-
tions or increasing the dose of current medications was ob-
served in 77 patients (68.8%), and addition of corticosteroids 
was observed in 37 patients (33%).
2. Outcomes of Patients with Clinical Remission of CD
In multivariate analysis, active inflammation on MRE in-
creased the risk for relapse (hazard ratio [HR], 6.985; 95% 
CI, 1.024−47.649), and the risk for the need for adding other 
medications or increasing the dose of current medications 
(HR, 6.440; 95% CI, 1.432−28.966) in patients with clinical 


















































































Fig. 2. Cumulative probabilities of a change in relapse (A) and the need for adding other medications or increasing the dose of current medications (B) 
according to magnetic resonance enterography (MRE) findings at the time of clinical remission. 
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the median albumin level were related to the risk for the 
need for adding other medications or increasing the dose of 
current medications. In the Kaplan-Meier analysis with the 
log-rank test, the presence of active inflammation on MRE 
imaging was significantly associated with higher cumulative 
probabilities of relapse (P =0.025), or the need for adding 
other medications or increasing the dose of current medica-
tions (P=0.029), compared with the absence of active inflam-
mation on MRE (Fig. 2).
Table 5. Univariate and Multivariate HR for Admission in Patients with Clinically Active CD
Outcomes Variable
Univariate Multivariate
HR (95% CI) P-value HR (95% CI) P-value
Admission Male sex 0.845 (0.483–1.477) 0.554 1.098 (0.600–2.013) 0.761
Age 0.977 (0.947–1.008) 0.140 - -
Age at diagnosis of CD 0.961 (0.924–1.000) 0.051 - -
Age at diagnosis of CD -
   A1 (Reference) (Reference)
   A2 0.571 (0.301–1.082) 0.086 0.547 (0.264–1.134) 0.105
   A3 0.345 (0.045–2.660) 0.307 0.092 (0.009–0.902) 0.041
BMI 0.963 (0.886–1.047) 0.381 - -
Disease duration 1.011 (0.965–1.059) 0.659 0.930 (0.867–0.997) 0.041
Smoking - -
   Current  0.587 (0.233–1.479) 0.258
   Former 0.697 (0.298–1.632) 0.405
   Never (Reference)
Baseline CDAI score 1.004 (1.000–1.007) 0.034 1.005 (1.000–1.009) 0.034
Baseline CRP level 1.008 (1.000–1.017) 0.055 - -
Baseline CRP >20 mg/dL 1.586 (0.933–2.696) 0.088 0.696 (0.353–1.374) 0.296
Baseline ESR level 1.009 (1.000–1.018) 0.060 - -
Baseline albumin level 0.477 (0.299–0.759) 0.002 - -
Baseline albumin ≤3.5 g/dL 2.528 (1.443–4.428) 0.001 1.923 (0.890–4.153) 0.096
Disease localization
   L1 (Reference) (Reference)
   L2 1.140 (0.322–4.042) 0.839 2.250 (0.560–9.042) 0.253
   L3 1.748 (0.920–3.321) 0.088 1.739 (0.796–3.800) 0.165
Disease behavior
   B1 (Reference) (Reference)
   B2 1.862 (0.907–3.819) 0.090 2.454 (1.096–5.493) 0.029
   B3 2.190 (1.147–4.184) 0.018 2.753 (1.196–6.336) 0.017
Perianal lesion 0.723 (0.428–1.220) 0.224 0.489 (0.276–0.868) 0.015
Previous surgery 0.595 (0.314–1.126) 0.110 - -
Family history of IBD 8.974 (2.918–27.596) <0.001 12.823 (3.469–47.391) <0.001
MRE findings
   Active inflammation 3.485 (1.259–9.649) 0.016 3.171 (1.092–9.204) 0.034
    Inactive (Reference) (Reference)
HR, hazard ratio; MRE, magnetic resonance enterography.
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3. Outcomes of Patients with Clinically Active CD
In multivariate analysis, active inflammation on MRE 
increased the risk for CD-related admission (HR, 2.970; 
95% CI, 1.006−8.772) in patients with clinically active CD 
(Table 5). According to the Montreal classification, patients 
who were diagnosed as having CD at age between 17 and 
40 years (A2) had a lower risk for the need for corticoste-
roids (HR, 0.413; 95% CI, 0.185−0.923) and for adding other 
medications or increasing the dose of current medications 
(HR, 0.373; 95% CI, 0.197−0.707). Stricturing disease (B2) 
(HR, 2.383; 95% CI, 1.005−5.383) or penetrating disease (B3) 
(HR, 2.795; 95% CI, 1.207−6.476) increased the risk for ad-
mission, compared with nonstricturing or nonpenetrating 
disease (B1). Penetrating disease (B3) increased the surgi-
cal risk (HR, 5.454; 95% CI, 1.094−27.178), and structuring 
disease (B2) showed a trend toward an increased risk of 
surgery (P=0.056). The cumulative probability of admission 
(P =0.009) was higher in patients with active inflammation 
on MRE imaging than in those without (Fig. 3).
DISCUSSION
Regular evaluation of disease activity in patients with CD 
is important to allow providing adequate medical or surgical 
therapy, and monitoring drug efficacies.21-23 Until recently, 
the goal of therapy for CD was only to eliminate disease-
related symptoms, improve the quality of life of patients, and 
maintain general wellness by minimizing adverse effects 
and long-term sequelae.24 In recent studies, the efficacy of 
CDAI as an indicator of disease severity has been found to 
be inconclusive.25,26 In our study, the CDAI score was not 
well correlated with the risk for relapse, surgery, or the need 
for other medications, except for the risk of admission (HR, 
1.005; 95% CI, 1.000−1.009) in patients with clinically active 
CD. Moreover, the CDAI score was not correlated with re-
lapse, admission, surgery, or the need for other medications 
in patients with clinical remission of CD.
The new goal of treatment is no longer only clinical remis-
sion indicated by a CDAI score of <150, but also the induc-
tion and maintenance of mucosal healing.24,27 Patients with 
both deep remission (defined as CDAI scores <150) and 
mucosal healing seem to have better outcomes than patients 
with only clinical remission or only mucosal healing.28,29 
Mucosal healing detected with MRE imaging was well corre-
lated with the disease activity of CD.8 In our study, mucosal 
healing detected with MRE was found in only 17 (27.9%) 
patients with clinical remission of CD and 19 (17%) patients 
with clinically active CD; however, there was no statistically 
significant difference (P =0.091). This implies that clinical 
symptoms according to the CDAI score are not correlated 
with the actual mucosal state detected with MRE imaging. 
Forty-four (72.1%) patients with clinical remission assessed 
according to clinical symptoms had active inflammation on 
MRE, which suggests that many patients without symptoms 
might have active intestinal inflammation.
MRE is now recommended as a new diagnostic tool in 
the management of CD.30 MRE is a radiation-free imaging 
technique used to obtain cross-sectional images of the small 
bowel, and can describe the whole of the gastrointestinal 
tract, including mucosal, mural, and extramural tissues.30 
Cross-sectional imaging is important in assessing diseases 
in parts of the small bowel that are difficult to reach by us-
ing enteroscopy.31 MRE also has a role in the detection of 
complications of small-bowel CD and postoperative CD 
recurrence.32 CD involvement of the proximal small bowel 
has a higher risk of stricturing behavior and the requirement 
for multiple surgeries.33 In our study, stricturing disease (B2) 
and penetrating disease (B3) according to the Montreal clas-
sification increased the risk for hospitalization by more than 
two times, compared with nonstricturing or nonpenetrating 
disease (B1) in patients with clinically active CD. Moreover, 
penetrating disease (B3) increased the risk for surgery by 
more than five times.
The current retrospective study provides evidence of the 
usefulness of MRE in assessing the prognosis of CD. The 
presence of active inflammation on MRE increased the risk 
(by more than six times) for relapse and the need for adding 










































Fig. 3. Cumulative probabilities of a change in admission according to 
the magnetic resonance enterography (MRE) findings during the clini-
cally active state. 
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tions in patients with clinical remission of CD. Moreover, the 
presence of active inflammation on MRE increased the risk 
for CD-related admission in patients with clinically active 
CD.
In a recent study, the radiologic response with CTE or 
MRE was associated with significant reductions in the long-
term risk of hospitalization, surgery, or corticosteroid use 
among patients with small-bowel CD, supporting our re-
sults.12 Complete radiologic response, defined as improve-
ment of all lesions at a second imaging study, decreased 
the risk for steroid use and surgery by >60% and the risk for 
hospitalization by 70%.12 In our study, we focused on the ef-
fects of the first findings of MRE imaging at the time of clini-
cal remission and during the clinically active state in patients 
with CD, separately. Moreover, we included patients with L2 
disease (colonic lesion) according to the Montreal classifica-
tion, and analyzed the risk of clinical relapse and the need 
for adding other medications or increasing the dose of cur-
rent medications. In this study, the risk of surgery and need 
for corticosteroids were not correlated with the initial MRE 
findings; however, the risk for clinical relapse, hospitalization, 
and the need for adding other medications or increasing the 
dose of current medications were significantly related to the 
findings of active inflammation on the initial MRE study.
This study has some limitations. As this was a retrospec-
tive study with a chart review, there was a timing difference 
between remission or relapse and MRE imaging in each 
patient. MRE imaging was done during a long-standing clini-
cal remission state in some patients, whereas other patients 
underwent imaging study immediately after clinical remis-
sion. We did not analyze the MRE findings with regard to 
mural thickening or edema because we only focused on the 
prognostic significance of the mucosal healing phase against 
active inflammation. Furthermore, MRE activity was not 
classified into specific degrees using previous alleged scor-
ing systems such as magnetic resonance index of activity 
(MaRIA), Crohn’s disease activity score (CDAS), or magnetic 
resonance enterography global score (MEGS). Prognosis 
could be affected by change of treatment options or physi-
cian’s decisions, but these factors were not considered. In 
addition, pediatric patients <18 years old were excluded, and 
we were not able to analyze the effects of anti-Saccharomy-
ces cerevisiae antibody and fecal calprotectin level because 
of a lack of data. Colonoscopic findings were not analyzed 
with MRE findings because there was a time difference 
between the days of colonoscopic examination and MRE 
imaging examination, and most patients had small-bowel 
involvement. Further studies about the correlation between 
endoscopic and MRE imaging findings are needed. In an-
other study, high CRP at the time of CD diagnosis was risk 
factor for hospitalization;34 however, we were not able to find 
a relationship between CRP level and prognosis. This report 
is the first study to evaluate the clinical outcomes of findings 
of active inflammation on MRE imaging in patients with CD.
In conclusion, the presence of active inflammation on 
MRE in patients with CD at the time of clinical remission 
was significantly associated with a high risk of relapse and 
the need for adding other medications or increasing the dose 
of current medications. Moreover, the presence of active in-
flammation during the clinically active state was significantly 
associated with an increased risk of hospitalization. MRE 
might be a useful technique in monitoring disease activity in 
patients with CD.
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